Syneron Medical Stock Rating Lowered by Zacks (ELOS)
Syneron Medical (NASDAQ:ELOS) was downgraded by Zacks to a “neutral” rating in a research note issued on Wednesday. They currently have a $10.80 target price on the stock. Zacks‘s price objective would indicate a potential upside of 2.18% from the company’s current price.
Syneron Medical (NASDAQ:ELOS) traded down 0.28% on Wednesday, hitting $10.53. The stock had a trading volume of 18,865 shares. Syneron Medical has a 52 week low of $8.04 and a 52 week high of $13.32. The stock has a 50-day moving average of $10.00 and a 200-day moving average of $10.74. The company has a market cap of $386.1 million and a price-to-earnings ratio of 57.08.
Syneron Medical (NASDAQ:ELOS) last released its earnings data on Wednesday, August 6th. The company reported $0.07 earnings per share for the quarter, meeting the analysts’ consensus estimate of $0.07. The company had revenue of $64.60 million for the quarter, compared to the consensus estimate of $63.52 million. During the same quarter last year, the company posted $0.02 earnings per share. Syneron Medical’s revenue was down 6.1% compared to the same quarter last year. Analysts expect that Syneron Medical will post $0.25 EPS for the current fiscal year.
Syneron Medical Ltd. designs, develops and markets aesthetic medical products based on its various technologies including its Electro-Optical Synergy (NASDAQ:ELOS), technology, which uses the synergy between electrical energy, including radiofrequency (RF) energy, and optical energy to provide aesthetic medical treatments.
To view Zacks’ full report, visit Zacks’ official website.
Receive News & Ratings for Syneron Medical Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneron Medical Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.